Mice that are prone to develop prostate tumors because they lack the PTEN tumor-suppressor protein remained cancer free when researchers disabled the growth-stimulating p110-beta protein, suggesting that this protein could be a promising prostate cancer drug target (Nature doi:10.1038/nature07091).
Mice that are prone to develop prostate tumors because they lack the PTEN tumor-suppressor protein remained cancer free when researchers disabled the growth-stimulating p110-beta protein, suggesting that this protein could be a promising prostate cancer drug target (Nature doi:10.1038/nature07091).
“The surprise is that p110-beta has been found to be a bigger player than p110-alpha in tumors that result from PTEN loss,” said Jean Zhao, PhD, of Dana-Farber Cancer Institute. “Now the drug companies that have been focusing on p110-alpha, will have to think about making p110-beta inhibitors as well.” The authors speculate that p110-beta may be providing a low-level but steady growth stimulus, and when PTEN is lost, it becomes an important source of cell proliferation signals.
Prolaris in Practice: Guiding ADT Benefits, Clinical Application, and Expert Insights From ACRO 2025
April 15th 2025Steven E. Finkelstein, MD, DABR, FACRO discuses how Prolaris distinguishes itself from other genomic biomarker platforms by providing uniquely actionable clinical information that quantifies the absolute benefit of androgen deprivation therapy when added to radiation therapy, offering clinicians a more precise tool for personalizing prostate cancer treatment strategies.